Close Menu

NEW YORK – Qiagen on Tuesday reported a 26 percent year-over-year increase in its preliminary third quarter revenues, both at actual and constant exchange rates, driven by COVID-19 testing and improved customer demand for other products.

The company booked $481.3 million in preliminary revenues for the quarter, up from $382.7 million during the same quarter last year. In July, Qiagen had predicted Q3 sales to grow between 16 percent and 21 percent. Analysts, on average, expect revenues of $461 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.

Nov
03
Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

Nov
18
Sponsored by
Genomenon

Rapid whole-genome sequencing (rWGS) is an emerging method that can provide molecular diagnosis in time to alter acute medical or surgical management and improve outcomes in acutely ill children.